CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias
Open Access
- 18 December 2025
- journal article
- Published by American Society of Hematology in Blood
- Vol. 146 (25) , 3019-3035
Abstract
Acute myeloid leukemias (AMLs) have an overall poor prognosis with many high-risk cases co-opting stem cell gene regulatory programs, but the mechanisms through which these programs are propogated remain poorly understood. The increased expression of the stem cell transcription factor, MECOM, underlies a key driver mechanism in largely incurable AMLs. However, how MECOM results in such aggressive AML phenotypes remains unknown. To address existing experimental limitations, we engineered and applied targeted protein degradation with functional genomic readouts to demonstrate that MECOM promotes malignant stem cell–like states by directly repressing prodifferentiation gene regulatory programs. Remarkably and unexpectedly, a single node in this network, a MECOM-bound cis-regulatory element located 42 kilobase (kb) downstream of the myeloid differentiation regulator CEBPA is both necessary and sufficient for maintaining MECOM-driven leukemias. Importantly, the targeted activation of this regulatory element promotes differentiation of these aggressive AMLs and reduces leukemia burden in vivo. These findings suggest a broadly applicable approach for functionally dissecting oncogenic gene regulatory networks to inform improved therapeutic strategies.Keywords
All Related Versions
This publication has 58 references indexed in Scilit:
- A longitudinal single-cell atlas of treatment response in pediatric AMLCancer Cell, 2023
- The 17‐gene stemness score associates with relapse risk and long‐term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemiaeJHaem, 2022
- Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1Oncology and Therapy, 2019
- Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and ImmunityCell, 2019
- Defining a Cancer Dependency MapCell, 2017
- A Remote GATA2 Hematopoietic Enhancer Drives Leukemogenesis in inv(3)(q21;q26) by Activating EVI1 ExpressionCancer Cell, 2014
- A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in LeukemiaCell, 2014
- Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid LeukemiaCancer Cell, 2014
- EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemiaLeukemia, 2010
- ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assaysJournal of Immunological Methods, 2009